Trial reportInternational forum of allergy & rhinology2026
Endoscopic Posterior Nasal Neurectomy Versus Radiofrequency Ablation in Refractory Allergic Rhinitis: A 2-Year Randomized Controlled Trial of Clinical Outcomes and Immunomodulatory Responses.
Trial report in International forum of allergy & rhinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Outcomes of Adjunctive Posterior Nasal Nerve Ablation With Medial Flap Inferior Turbinoplasty.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundEndoscopic posterior nasal nerve (PNN) neurectomy and temperature-controlled radiofrequency ablation are validated interventions for medication-refractory allergic rhinitis (AR), but direct comparisons of their long-term efficacy, safety, and mechanisms remain lacking.
methodsIn this prospective, multicenter, randomized, patient-blinded study, 174 adults with moderate-to-severe persistent AR were allocated to PNN neurectomy (n = 89) or ablation (n = 85). The primary endpoint was the percentage of participants achieving the minimal clinically important difference (MCID) for the 24-h reflective total nasal symptom score (rTNSS) at 24 months.
resultsThe rTNSS MCID responder rate at 24 months was 86.5% (95% confidence interval [CI], 80.0-95.0%) in the neurectomy group and 84.9% (95% CI, 78.0-94.0%) in the ablation group, with no significant between-group difference (p = 0.453). Both groups demonstrated substantial and parallel improvements in quality of life. Neurectomy provided greater and more durable control of rhinorrhea (1-24 months, all p < 0.05), nasal congestion (24 months, p < 0.001), and nasal itching (24 months, p = 0.046), alongside a greater reduction in unilateral nasal resistance (right side, p = 0.014). Both groups showed convergent systemic neuroimmune reprogramming at 1 year, with suppression of substance P, interleukin (IL)-31, IL-33, IL-4, IL-13, and IL-6, and increased transforming growth factor-β (TGF-β)and immunoglobulin G4 (IgG4). No serious adverse events occurred; mild transitory events were reported only with neurectomy (3.4%).
conclusionBoth techniques are effective and safe for refractory AR over 2 years. Although overall outcomes are comparable, neurectomy offers superior and sustained control of rhinorrhea, nasal congestion, and nasal itching. Treatment can be individualized based on symptom profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.